The agency approved the drug based on a study that showed an 88 percent response rate in young patients with ALK-positive anaplastic large cell lymphoma.
On the first day, Amgen detailed the rapid advancement of its KRAS inhibitor and Tempus unveiled an AI device to help oncologists deliver precision oncology.
Although the pandemic may have been at the forefront of readers' minds, they remained interested in the latest advances and controversies in precision oncology.
The agency made its decision based on data showing adjuvant Tagrisso decreased the risk of cancer recurrence or death by 80 percent compared to placebo.